Le Lézard
Classified in: Science and technology
Subject: PDT

LambdaTest introduces an AI-powered Test Failure Analysis feature in its smart test orchestration platform HyperExecute

With this feature, customers can ensure higher-quality software development, reduced time-to-market, and enhanced customer satisfaction

NOIDA, India and SAN FRANCISCO, June 6, 2023 /PRNewswire/ -- LambdaTest, an intelligent and unified enterprise test execution cloud platform, has introduced an AI-powered test failure analysis feature in HyperExecute, its blazing-fast, smart test execution and orchestration platform. This path-breaking new feature will enable digital businesses to streamline their troubleshooting and remediation process for test case failures in a single click.


With the new feature, HyperExecute users will no longer have to do the time-consuming and cumbersome manual test log analysis. The platform will categorize errors, enabling swift identification of failure types, thereby saving time and increasing developer feedback velocity.

After identifying the failure type, LambdaTest will offer a structured approach to address it through precise corrective measures or recommended remedies. This targeted approach empowers users to do a quicker resolution of failure by eliminating unnecessary manual steps and instead optimizing for efficiency.

"With the introduction of AI-powered test failure analysis, we are significantly reducing the time required for root cause analysis (RCA). Our overall aim is to enhance the productivity of testing teams by elevating the efficiency and effectiveness of the QA process. With this feature, development teams can now concentrate their efforts on implementing accurate solutions. This is a fundamental shift from a blunt test execution platform to an AI-powered test orchestration co-pilot that assists developer and QA teams in every stage of quality validation. The resulting reduction in turnaround time facilitates faster bug fixes, higher-quality software development, reduced time-to-market, and enhanced end-customer satisfaction," said Mayank Bhola, Co-founder and Head of Product, LambdaTest.

Also, LambdaTest has added new features to its test intelligence analytics platform to enable users to have enhanced control over Selenium command logs. Key features include quick issue identification, response statuses over time, endpoint usage analysis, and bug fixes prioritization.

For more details, visit: https://www.lambdatest.com/test-intelligence/failure-analysis

About LambdaTest

LambdaTest is an AI-powered unified enterprise test execution cloud platform that helps businesses drastically reduce time to market through faster test execution, ensuring quality releases and accelerated digital transformation. Over 10,000+ enterprise customers and 2+ million users across 130+ countries rely on LambdaTest for their testing needs.

For more information, please visit, https://www.lambdatest.com or contact the LambdaTest press office: press@lambdatest.com

Logo: https://mma.prnewswire.com/media/1721228/Lambda_Test_Logo.jpg

These press releases may also interest you

at 17:07
The American Concrete Institute along with the ACI Saudi Chapter will co-host the ACI Concrete Conference of Codes, Standards, and Best Practices in Riyadh, Saudi Arabia on November 28-29, 2023. The 2-day conference will be held at the Hilton Riyadh...

at 17:05
Quanterix Corporation , a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will speak on a panel at Goldman Sachs Alzheimer's Disease Day on Tuesday, October...

at 17:05
MEI Pharma, Inc. (the "MEI" or "the Company") today issued the following statement in response to the consent solicitation initiated by a group led by Anson Advisors Inc. and Cable Car Capital LLC. The MEI Board of Directors and management team...

at 17:05
BlackBerry Limited today reported financial results for the three months ended August 31, 2023 (all figures in U.S. dollars and U.S. GAAP, except...

at 17:01
DelveInsight's Neuroblastoma Market Insights report includes a comprehensive understanding of current treatment practices, neuroblastoma emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to...

at 17:00
Medicenna Therapeutics Corp. ("Medicenna" or the "Company") , a clinical-stage immuno-oncology company focused on the development of novel Superkines, today announced the voting results from the Company's annual and special meeting of shareholders...

News published on and distributed by: